MedPath
Found 2 clinical trials|View Analysis
Sort by:

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Phase 4
Recruiting
Conditions
Type 2 Diabetes
Interventions
Drug: iGlarLixi (insulin glargine/lixisenatide)
First Posted Date
2024-12-04
Last Posted Date
2024-12-04
Lead Sponsor
Sanofi
Target Recruit Count
105
Registration Number
NCT06716424
Locations
🇮🇳

Investigational Site Number : 3560009, Bengaluru, India

🇮🇳

Investigational Site Number : 3560011, Jaipur, India

🇮🇳

Investigational Site Number : 3560008, Pune, India

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Phase 4
Recruiting
Conditions
Type 2 Diabetes (T2D)
Interventions
Drug: iGlarLixi (insulin glargine/lixisenatide)
Drug: Gla-100 (insulin glargine)
First Posted Date
2024-11-04
Last Posted Date
2024-12-12
Lead Sponsor
Sanofi
Target Recruit Count
678
Registration Number
NCT06671587
Locations
🇨🇳

Investigational Site Number: 1560001, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath